$100 for a Covid-19 vac­cine? That's what Mod­er­na says may be com­ing

As Mod­er­na piv­ots away from Covid-19 to oth­er vac­cines, the mR­NA-fo­cused biotech is still plot­ting how it could hit $13 bil­lion in an­nu­al US Covid-19 vac­cine sales, with $100 shots and 50% of all adults get­ting a boost­er.

But the Boston-based com­pa­ny’s lofty ex­pec­ta­tions, re­vealed in a slide show yes­ter­day as part of its R&D day, in­clud­ed an es­ti­mate that the world­wide pan­dem­ic Covid-19 vac­cines mar­ket is worth more than $100 bil­lion glob­al­ly, as in high-in­come coun­tries, the el­i­gi­ble high-risk pop­u­la­tion (el­der­ly and those with high risk) is about 340 mil­lion peo­ple.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN